Published in
American Society of Hematology, Blood, 19(129), p. 2616-2623, 2017
DOI: 10.1182/blood-2016-10-744292
Links
Tools
Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report
Journal article published in 2017 by
Mira Tout,
Olivier Casasnovas 
,
Michel Meignan,
Thierry Lamy,
Franck Morschhauser,
Gilles Salles,
Emmanuel Gyan,
Corinne Haioun,
Mélanie Mercier,
Pierre Feugier,
Sami Boussetta,
Gilles Paintaud,
David Ternant,
Guillaume Cartron
,
Michel Meignan,
Thierry Lamy,
Franck Morschhauser,
Gilles Salles,
Emmanuel Gyan,
Corinne Haioun,
Mélanie Mercier,
Pierre Feugier,
Sami Boussetta,
Gilles Paintaud,
David Ternant,
Guillaume Cartron
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points Rituximab exposure decreased as metabolic tumor volume increased, and correlated with metabolic response and survival. Rituximab dose could be individualized according to metabolic tumor volume to achieve optimal exposure and therefore optimal response.